DNMT3A and myelodysplastic syndrome: Unlike in AML and MDS, most mutations in overgrowth syndrome do not directly affect the catalytic activity of DNMT3A, but interfere with domain–domain interactions and histone binding, which further affect the activity of DNMT3A (Tatton-Brown et al., 2014).